Drug Trial Radar · NCT07850765
Real-World Patient and Physician Experience With Semaglutide Across Six Emerging Markets
Last checked: Nov 19, 2026Latest source record: Sep 30, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,260
Actual
Start
Aug 28, 2026
Primary completion
Aug 31, 2026
Study completion Aug 31, 2026
Sponsor
- Lead sponsor
- Novo Nordisk A/SNovo Nordisk (NVO)
- Sponsor type
- Industry
- First posted
- Sep 30, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess semaglutide's impact on daily life from participants and physicians experience.
Conditions
- Overweight
- Obesity
Interventions
SemaglutideDrug
This is a retrospective, non-interventional study; therefore, no intervention was administered as part of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change in Food Noise Questionnaire (FNQ) scoreTime frame: At data capture (Day 1)
- Change in Body WeightTime frame: At data capture (Day 1)
- Health-Related Quality of Life Measured by EQ-5D-5LTime frame: At data capture (Day 1)
- Health Status Measured by EQ Visual Analogue Scale (EQ-VAS)Time frame: At data capture (Day 1)
- Medication Adherence Measured by Adelphi Adherence Questionnaire (ADAQ)Time frame: At data capture (Day 1)
- Number of Participant Satisfaction With WegovyTime frame: At data capture (Day 1)
- Change in Body Mass Index (BMI)Time frame: At data capture (Day 1)
- Percent Change in Body WeightTime frame: At data capture (Day 1)
- Number of Participants with Achievement of Weight-Loss TargetTime frame: At data capture (Day 1)
- Number of Participants who Concern About Future Weight GainTime frame: At data capture (Day 1)
- Impact of Wegovy on Weight-Related BurdenTime frame: At data capture (Day 1)
- Impact of Wegovy on Daily Life and Health BehavioursTime frame: At data capture (Day 1)
Locations
6 sites in 6 countries. Site status is shown where the registry gives one.
Novo Nordisk Investigational Site
Jerusalem, Israel
Novo Nordisk Investigational Site
Mexico City, Mexico
Novo Nordisk Investigational Site
Riyadh, Saudi Arabia
Novo Nordisk Investigational Site
Pretoria, South Africa
Novo Nordisk Investigational Site
Ankara, Turkey (Türkiye)
Novo Nordisk Investigational Site
Abu Dhabi, United Arab Emirates
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.